How Many Doses Vial FOXO4-DRI? (Reconstitution Guide)

How Many Doses Vial FOXO4-DRI? (Reconstitution Guide)

A 5mg vial of FOXO4-DRI doesn't come with a fixed number of doses. The yield depends entirely on your target concentration, planned dosage per administration, and total reconstitution volume. Most research protocols using FOXO4-DRI (a senolytic peptide designed to selectively induce apoptosis in senescent cells) employ doses ranging from 0.25mg to 0.5mg per administration, which means a single 5mg vial can yield anywhere from 10 to 20 individual doses when reconstituted with 2mL of bacteriostatic water. However, if your protocol requires higher per-dose concentrations or lower total dilution volumes, that same vial might provide only 6–8 administrations.

How many doses does a vial of FOXO4-DRI provide?

A standard 5mg FOXO4-DRI vial reconstituted with 2mL bacteriostatic water yields 10–20 doses at research-standard concentrations of 0.25mg–0.5mg per administration. The exact number depends on your target dose, reconstitution volume, and whether your protocol uses daily or intermittent dosing schedules. Peptide stability post-reconstitution limits usable yield to approximately 28 days under refrigeration.

Yes, you can calculate exactly how many doses a vial of FOXO4-DRI will provide. But the answer isn't printed on the label. Unlike pre-filled pharmaceutical products with fixed dosing (such as GLP-1 receptor agonists like semaglutide or tirzepatide), research-grade lyophilised peptides require reconstitution, and dosage is determined by the researcher based on study design, subject weight, and administration frequency. The rest of this piece covers exactly how reconstitution volume affects concentration, what dosage ranges appear most frequently in published senolytic research, and what preparation mistakes reduce the effective number of usable doses from a single vial.

Understanding FOXO4-DRI Concentration and Reconstitution Variables

The number of doses you extract from a FOXO4-DRI vial is a function of three variables: the mass of peptide in the vial (typically 5mg for research-grade products), the volume of bacteriostatic water used to reconstitute it, and the target dose per administration your protocol requires. FOXO4-DRI (Forkhead box protein O4-D-Retro-Inverso) is a modified peptide that disrupts the interaction between FOXO4 and p53 in senescent cells, triggering selective apoptosis without affecting healthy cells. A mechanism first characterised in a 2017 Cell study by Baar et al. that demonstrated significant clearance of senescent cells in naturally aged mice.

When you reconstitute a 5mg vial with 2mL of bacteriostatic water, the resulting concentration is 2.5mg/mL. If your research protocol calls for 0.5mg per dose, you would draw 0.2mL (200 microlitres) per administration, yielding exactly 10 doses from that vial. If your target dose is 0.25mg, you draw 0.1mL per administration, and the same vial now provides 20 doses. Conversely, reconstituting with only 1mL of water produces a 5mg/mL concentration. Higher potency per unit volume, but the same 5mg total peptide mass, meaning your dose count remains tied to how much peptide you administer per injection, not the concentration of the solution.

Most published senolytic research involving FOXO4-DRI in animal models uses doses in the range of 5–10 mg/kg body weight administered via subcutaneous or intraperitoneal injection. Translating that to human-equivalent dosing using standard allometric scaling (dividing the animal dose by approximately 12.3 for mouse-to-human conversion) suggests research-equivalent doses in the neighborhood of 0.4–0.8 mg/kg. For a 70kg adult, that implies a per-administration dose of approximately 28–56mg. Far exceeding what a single 5mg vial provides. However, in vitro studies and exploratory human research protocols often employ significantly lower doses to assess tolerability and biomarker response before escalating, which is where the 0.25mg–0.5mg per-dose range becomes relevant for initial-phase investigations.

Our experience working with research teams using FOXO4-DRI has shown that most preliminary protocols start with conservative dosing to evaluate senescent cell clearance biomarkers (such as circulating p16INK4a-positive cells or inflammatory cytokines like IL-6 and TNF-alpha) before increasing dose or frequency. Starting at 0.25mg per administration allows a single 5mg vial to support a 20-dose exploratory cycle. Sufficient for daily dosing over three weeks or intermittent dosing (every 3–4 days) across an eight-week observation period. The reconstitution math is straightforward, but the biological half-life and peptide stability post-reconstitution impose practical limits that reduce the theoretical maximum yield.

Peptide Stability and the Real-World Dose Yield Ceiling

Calculating how many doses a vial of FOXO4-DRI contains is only half the equation. The other half is how long the reconstituted peptide remains stable enough to deliver those doses at full potency. Lyophilised peptides stored at −20°C before reconstitution can remain stable for 12–24 months, but once you add bacteriostatic water, the clock starts. Reconstituted peptides are susceptible to hydrolysis, oxidation, and microbial contamination, even under refrigeration at 2–8°C. Industry-standard guidance for most research-grade peptides, including FOXO4-DRI, is to use reconstituted solutions within 28 days. Beyond that window, degradation accelerates and potency cannot be guaranteed.

That 28-day stability window establishes a practical ceiling on usable doses. If your protocol requires 0.25mg per dose and you reconstitute a 5mg vial to yield 20 theoretical doses, but you administer only once every four days, you're looking at approximately seven administrations within the 28-day window. Leaving 13 doses' worth of peptide that will degrade before use. The solution is either more frequent dosing, smaller reconstitution volumes to increase per-administration draw volume (reducing the total number of separate needle punctures into the vial, which introduces contamination risk), or splitting the original lyophilised powder into smaller aliquots before reconstitution (a technique that requires sterile technique and is typically reserved for advanced laboratory settings).

Bacteriostat in the reconstitution water. Typically 0.9% benzyl alcohol. Prevents bacterial growth, but it does not stop peptide degradation. The primary mechanism of peptide breakdown post-reconstitution is oxidation of methionine and cysteine residues and hydrolysis of peptide bonds, both of which are temperature-dependent. Storing reconstituted FOXO4-DRI at 2–8°C (standard refrigeration) significantly slows these reactions compared to room temperature, but does not halt them. One study published in the Journal of Pharmaceutical Sciences found that certain peptides lost up to 15% potency after 30 days at 4°C. Well within the refrigerated storage range most researchers use.

The biggest mistake we see when researchers calculate how many doses a vial of FOXO4-DRI provides is ignoring the stability-imposed ceiling and assuming every theoretical dose is usable. If you're running a daily-dosing protocol, a 5mg vial reconstituted to 20 doses at 0.25mg each will be fully consumed within 20 days. Well within the 28-day stability window. But if your protocol spaces doses 5–7 days apart (a common intermittent senolytic schedule based on the clearance kinetics of senescent cells), you'll only extract 4–6 usable doses before the peptide degrades. In that scenario, reconstituting the vial to a higher concentration (1mL instead of 2mL) and drawing larger volumes per dose allows you to finish the vial sooner, minimizing waste.

Dosage Protocols and Real-World Yield Scenarios

Different research designs yield vastly different practical dose counts from the same 5mg vial of FOXO4-DRI. Understanding the relationship between administration frequency, target dose, and peptide stability is what separates a well-designed protocol from one that wastes expensive research compounds. Let's walk through three representative scenarios that illustrate how reconstitution decisions directly determine usable yield.

Scenario 1: Daily Low-Dose Senolytic Exploration (0.25mg/day)
Reconstitute 5mg FOXO4-DRI with 2mL bacteriostatic water → concentration = 2.5mg/mL. Target dose = 0.25mg per day. Draw volume per dose = 0.1mL. Total theoretical doses = 20. Administration schedule: one dose per day. Timeline to consume all doses: 20 days. Stability window: 28 days. Usable yield: 20 doses. The entire vial is consumed well before degradation becomes a factor. This is the most efficient use case for maximizing dose count from a single vial.

Scenario 2: Intermittent Moderate-Dose Protocol (0.5mg every 4 days)
Reconstitute 5mg FOXO4-DRI with 1mL bacteriostatic water → concentration = 5mg/mL. Target dose = 0.5mg every four days. Draw volume per dose = 0.1mL. Total theoretical doses = 10. Administration schedule: one dose every four days. Timeline to consume all doses: 40 days. Stability window: 28 days. Usable yield: 7 doses. The eighth dose would fall on day 32, beyond the recommended stability window. Three doses' worth of peptide (1.5mg) will degrade unused. To avoid waste, either increase dosing frequency or split the vial before reconstitution.

Scenario 3: High-Dose Acute Research Phase (1mg twice weekly)
Reconstitute 5mg FOXO4-DRI with 1mL bacteriostatic water → concentration = 5mg/mL. Target dose = 1mg twice per week (every 3–4 days). Draw volume per dose = 0.2mL. Total theoretical doses = 5. Administration schedule: two doses per week. Timeline to consume all doses: 15 days. Stability window: 28 days. Usable yield: 5 doses. All doses consumed well before the stability ceiling. This protocol uses the peptide efficiently but requires multiple vials if the research phase extends beyond 2.5 weeks.

The pattern is clear: higher per-dose amounts and more frequent administration maximize the usable yield from each vial by ensuring the peptide is consumed before degradation. Conversely, infrequent low-dose schedules leave reconstituted peptide sitting in the vial for weeks, which reduces effective yield regardless of how carefully you calculate concentration. Real Peptides manufactures FOXO4-DRI in small-batch lyophilised form specifically to support this kind of flexible dosing. But the flexibility only matters if you plan reconstitution and dosing schedules together, not separately.

FOXO4-DRI Vial Yield: Concentration Comparison

Before reconstituting your vial, compare how different water volumes affect concentration, dose count, and practical yield. The table below maps reconstitution volume to resulting concentration and the number of doses you'll extract at common research dosages.

The 'Stability-Limited Yield' column assumes dosing every four days, which is a common intermittent senolytic schedule. Notice that regardless of reconstitution volume, you hit the same 7-dose ceiling when spacing administrations that far apart. Proving that administration frequency, not concentration, is the limiting factor in real-world yield for infrequent protocols.

Key Takeaways

• A 5mg vial of FOXO4-DRI reconstituted with 2mL bacteriostatic water yields 10–20 doses depending on whether you administer 0.5mg or 0.25mg per injection. Concentration is a function of reconstitution volume, not vial size.
• Reconstituted peptides remain stable for approximately 28 days under refrigeration at 2–8°C. Protocols with infrequent dosing (every 5–7 days) will hit the stability ceiling before consuming all theoretical doses, wasting peptide.
• FOXO4-DRI research protocols in published literature typically employ doses of 5–10 mg/kg in animal models, translating to approximately 0.4–0.8 mg/kg human-equivalent after allometric scaling. Preliminary human research often starts significantly lower at 0.25–0.5mg per administration to assess tolerability.
• Bacteriostatic water prevents microbial contamination but does not stop peptide degradation via oxidation and hydrolysis. Storing reconstituted FOXO4-DRI above 8°C accelerates breakdown and reduces usable yield.
• Drawing smaller volumes per dose (by using higher-concentration reconstitutions) reduces the total number of needle punctures into the vial, lowering contamination risk but increasing measurement error for very low doses.

What If: FOXO4-DRI Dosing Scenarios

What If I Reconstitute a 5mg Vial But Only Need 3 Doses Before My Protocol Ends?

Reconstitute only what you'll use within 28 days, or split the lyophilised powder before adding water. If your protocol requires only three doses of 0.5mg each (1.5mg total peptide), reconstituting the full 5mg vial wastes 3.5mg. The solution: if you have access to a sterile environment and weighing equipment, divide the lyophilised powder into smaller portions (e.g., three separate vials with approximately 1.7mg each) before reconstitution. This technique requires milligram-precision scales and sterile handling to avoid contamination. Alternatively, design your protocol to use the full vial within the stability window. Three doses spaced across two weeks consumes only 1.5mg, but extending the protocol to include additional biomarker measurement timepoints at days 7, 14, and 21 (six total doses at 0.5mg each) uses 3mg and still finishes within 28 days.

What If My Protocol Requires 2mg Per Dose But I Only Have 5mg Vials?

You'll need multiple vials per dose, or you'll need to source higher-mass vials if available. A 5mg vial provides only 2.5 doses at 2mg each. Not enough for most research timelines. Reconstituting two 5mg vials together in a single larger sterile vial (creating 10mg total peptide) with 2mL bacteriostatic water gives you a 5mg/mL concentration, and drawing 0.4mL per administration delivers exactly 2mg per dose for five total administrations. However, combining vials increases contamination risk during transfer. The cleaner approach: reconstitute each 5mg vial separately with 1mL water (5mg/mL concentration), draw 0.4mL from the first vial (2mg), then 0.4mL from a second vial to complete the dose. This uses 4mg from two vials per administration, leaving residual peptide in each. Less efficient but lower contamination risk.

What If I Store Reconstituted FOXO4-DRI in the Freezer to Extend Stability Beyond 28 Days?

Freezing reconstituted peptides often causes irreversible aggregation and potency loss. Refrigeration at 2–8°C is the maximum safe storage condition. The mechanism: water molecules form ice crystals during freezing, which physically disrupt the three-dimensional structure of dissolved peptides, causing aggregation (clumping of peptide molecules) that renders them biologically inactive. Some peptides tolerate freeze-thaw cycles when stored in specific cryoprotectant solutions (such as glycerol or DMSO), but bacteriostatic water does not provide that protection. If you need extended storage, keep the peptide in lyophilised (freeze-dried powder) form at −20°C and reconstitute only the portion you'll use within 28 days. A 5mg vial stored as powder remains stable for 12–24 months; the same vial reconstituted and frozen will likely lose 30–60% potency after a single freeze-thaw cycle.

What If I Draw Slightly Different Volumes Each Time — Does That Affect Total Dose Count?

Measurement variability reduces effective yield by wasting peptide in over-draws and under-dosing in short-draws. If your target dose is 0.5mg from a 2.5mg/mL solution (requiring exactly 0.2mL per draw), but you consistently draw 0.22mL due to syringe dead space or measurement error, you're administering 0.55mg per dose instead of 0.5mg. A 10% over-dose that reduces your total yield from 10 doses to approximately 9 doses. Using insulin syringes with 0.01mL graduation marks (1-unit increments on a U-100 syringe) significantly improves measurement precision compared to standard 1mL or 3mL syringes. The practical floor for reliable manual measurement is approximately 0.05mL (5 units on a U-100 syringe). Doses requiring smaller draw volumes should use higher-concentration reconstitutions to bring the draw volume above that threshold.

The Scientific Truth About FOXO4-DRI Dosing Per Vial

Here's the honest answer: the number of doses in a FOXO4-DRI vial is not a product specification. It's a research design decision you make when you choose your reconstitution volume and target dose. Unlike FDA-approved medications with fixed dosing (where one pen delivers a set number of clicks at a defined microgram amount), research peptides like FOXO4-DRI require you to understand peptide concentration, solution stability, and administration math. Most researchers overestimate usable yield because they calculate theoretical doses without accounting for the 28-day stability window or the measurement precision limits of their syringes.

The evidence is clear: a 5mg vial provides 10–20 administrations at research-standard doses of 0.25–0.5mg each when reconstituted with 1–2mL bacteriostatic water. But only if your dosing schedule consumes the peptide before it degrades. Infrequent protocols (dosing every 5–7 days) hit the stability ceiling at 4–7 usable doses regardless of how you reconstitute, because the remaining peptide degrades before you can administer it. The solution is not larger vials or more concentrated solutions. It's aligning your reconstitution volume and dosing frequency so the vial is consumed within 28 days. Peptide research requires planning the entire protocol before you add the first drop of water.

Every peptide we supply at Real Peptides. Including FOXO4-DRI. Is manufactured through small-batch synthesis with exact amino-acid sequencing to guarantee purity and consistency. That precision extends to the lyophilised mass in each vial, which is verified by HPLC before shipping. But precision in manufacturing doesn't eliminate the need for precision in reconstitution and administration. Understanding how many doses your vial provides requires you to define 'dose' first. Then calculate backward to determine the reconstitution strategy that maximizes usable yield without exceeding the stability window. Most guides stop at the concentration formula; real-world protocols demand you think three steps ahead.

If you're planning senolytic research and need guidance on dosing strategy, peptide handling, or protocol design around FOXO4-DRI or other research-grade compounds like Epithalon, our team has supported hundreds of research teams through exactly this process. Explore our full peptide collection to see how small-batch precision and rigorous quality control create research tools that deliver reproducible, reliable results across every vial you reconstitute.